Using a CoxPH model based on the predicted ER activity score, age and stage, we were able to identify ER + /HER2- breast cancer patients from a testing cohort with high risk of progressive disease and even had poorer survival than TNBC patients. This evidence concerns the gene ESR1 and breast carcinoma.